This review highlights the emerging role of inflammatory cytokines, specifically Interleukin-6, in the pathogenesis and vascular remodeling of pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
IL-6 pathway merits targeted trials in pulmonary hypertension; leaves open whether anti-cytokine therapy improves outcomes.
Pulmonary hypertension is an "umbrella term" used for a spectrum of entities resulting in an elevation of the pulmonary arterial pressure. Clinical symptoms include dyspnea and fatigue which in the absence of adequate therapeutic intervention may lead to progressive right heart failure and death. The pathogenesis of pulmonary hypertension is characterized by three major processes including vasoconstriction, vascular remodeling and microthrombotic events. In addition accumulating evidence point to a cytokine driven inflammatory process as a major contributor to the development of pulmonary hypertension.This review summarizes the latest clinical and experimental developments in inflammation associated with pulmonary hypertension with special focus on Interleukin-6, and its role in vascular remodeling in pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Groth et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: